Veradermics (MANE) Enterprise Value (2024 - 2026)

Veradermics (MANE) posted Enterprise Value of -$390.8 million for Q1 2026, down 175.48% on a QoQ basis from -$141.9 million in Q4 2025.

Veradermics (MANE) Enterprise Value (2024 - 2026) Analysis & Trends

Veradermics' Enterprise Value history runs 3 years deep, the most recent figure standing at -$390.8 million for Q1 2026.

Quarterly Enterprise Value changed N/A year-over-year to -$390.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$390.8 million (changed N/A YoY) and the FY2025 annual result came in at -$141.9 million, down 167.24% from the prior year.
Enterprise Value was -$390.8 million for Q1 2026 at Veradermics, down from -$141.9 million in the prior quarter.
Across five years, Enterprise Value topped out at -$53.1 million in Q4 2024 and bottomed at -$390.8 million in Q1 2026.
A 3-year average of -$195.2 million and a median of -$141.9 million in 2025 frame the typical range for Enterprise Value.
Peak annual rise in Enterprise Value reached 167.24% in 2025, while the deepest fall reached 167.24% in 2025.
Veradermics' Enterprise Value stood at -$53.1 million in 2024, then sank by 167.24% to -$141.9 million in 2025, then plunged by 175.48% to -$390.8 million in 2026.
Business Quant data shows MANE's Enterprise Value at -$390.8 million in Q1 2026, -$141.9 million in Q4 2025, and -$53.1 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Enterprise Value (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-283.54 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-61.40 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-4.79 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	-32.26 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-7.25 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-8.75 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-5.18 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-1.91 Bn
10	Veradermics	2.63 Bn	2.63 Bn	-	-390.80 Mn

Download Data